EV + Pembro Beats SOC in Cisplatin-Ineligible Bladder Cancer – Medscape

Written by

admin

in

  1. EV + Pembro Beats SOC in Cisplatin-Ineligible Bladder Cancer  Medscape
  2. Merck rolls out some showstoppers at a major cancer conference. Its future may depend on them  statnews.com
  3. Merck announces KEYTRUDA, Padcev trial showed improvements in EFS  TipRanks
  4. Astellas-Pfizer’s combination therapy halves risk of death in bladder cancer patients  The Hindu
  5. PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer  Pfizer

Continue Reading

More posts